Skip to main content
Technology Talk - An introduction to dbDNA™ and mbDNA™

Technology Talk – An introduction to dbDNA™ and mbDNA™

In this webinar, Touchlight’s Elena Stoyanova, PhD introduces the company’s innovative DNA manufacturing technologies, focusing on their proprietary dbDNA™ (Doggybone ...
Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model

Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model

Learn how doggybone DNA (dbDNA™) vaccines offer a safe, scalable alternative to plasmid DNA for cancer immunotherapy, delivering strong immune ...
Optimizing a linear ‘Doggybone’ DNA vaccine for influenza virus through the incorporation of DNA targeting sequences and neuraminidase antigen

Optimizing a linear ‘Doggybone’ DNA vaccine for influenza virus through the incorporation of DNA targeting sequences and neuraminidase antigen

This article explores the development of an optimized linear DNA vaccine for influenza using Touchlight’s dbDNA™ platform. By incorporating neuraminidase ...
Enzymatically amplified linear dbDNA™ as a rapid and scalable solution to industrial lentiviral vector manufacturing

Enzymatically amplified linear dbDNA™ as a rapid and scalable solution to industrial lentiviral vector manufacturing

This article explores how Touchlight’s enzymatically amplified linear dbDNA™ technology overcomes the limitations of traditional plasmid-based methods in lentiviral vector ...
Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines

Comparative analysis of enzymatically produced novel linear DNA constructs with plasmids for use as DNA vaccines

This article presents a comparative study between traditional plasmid DNA vaccines and novel enzymatically produced linear DNA constructs known as ...
Novel synthetic plasmid and DoggyboneTM DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice

Novel synthetic plasmid and DoggyboneTM DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice

CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are ...
Doggybone™ DNA: an advanced platform for AAV production

Doggybone™ DNA: an advanced platform for AAV production

Recombinant AAV is a powerful vector for gene delivery—but its full potential is held back by the limitations of plasmid ...
Leveraging Synthetic DNA in AAV Manufacturing to Increase Efficiency

Leveraging Synthetic DNA in AAV Manufacturing to Increase Efficiency

Discover how synthetic, backbone-free DNA offers a safer, scalable alternative to traditional plasmid DNA for AAV production, addressing key challenges ...
CAR T Cell Generation by piggyBac Transposition from Linear dbDNA Vectors Requires Transposon DNA-Flanking Regions

CAR T Cell Generation by piggyBac Transposition from Linear dbDNA Vectors Requires Transposon DNA-Flanking Regions

CAR T cell therapy has shown remarkable success in treating blood cancers, but current production methods using viral vectors are ...
Enabling better non-viral gene therapy with mbDNA – a circular ssDNA

Enabling better non-viral gene therapy with mbDNA – a circular ssDNA

Enabling better non-viral gene therapy with mbDNA–a circular ssDNA Download the poster here: 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 ...
Improved CRISPR Gene Editing with dbDNA as a Knock-In Template

Improved CRISPR Gene Editing with dbDNA as a Knock-In Template

Touchlight’s robust and rapidly scalable manufacturing technology, offers a reliable and effective alternative to pDNA as a knock-in template for ...
Addressing pDNA challenges in large-scale manufacturing of rAAV and rLV

Addressing pDNA challenges in large-scale manufacturing of rAAV and rLV

As gene therapy accelerates, the demand for scalable viral vector manufacturing has never been greater. Yet traditional plasmid DNA (pDNA) ...
dbDNA as a rapid and scalable solution to industrial lentiviral vector manufacturing

dbDNA as a rapid and scalable solution to industrial lentiviral vector manufacturing

Here, we demonstrate that dbDNATM can be optimised for the manufacture of high titre LVV ...
SARS-CoV-2 Doggybone DNA vaccine produces cross-variant veutralising antibodies and is protective in a COVID-19 animal model

SARS-CoV-2 Doggybone DNA vaccine produces cross-variant veutralising antibodies and is protective in a COVID-19 animal model

The most effective way to end the COVID-19 pandemic is through the development of medical countermeasures to combat SARS-CoV-2 infection ...
Safe and Stable Generation of Human iPSCs Using dbDNA™ Vectors

Safe and Stable Generation of Human iPSCs Using dbDNA™ Vectors

Induced pluripotent stem cells (iPSCs) represent a transformative platform for regenerative medicine and cell therapy, but clinical success depends on ...
Accelerating RNA manufacturing with GMP-compliant dbDNA technologies

Accelerating RNA manufacturing with GMP-compliant dbDNA technologies

Touchlight’s dbDNA (doggybone DNA) is a novel and disruptive advancement in DNA manufacturing technology, designed to overcome the limitations of ...
Enabling Cost-Effective, Rapid Access to RNA Vaccines and Therapeutics with z- dbDNA

Enabling Cost-Effective, Rapid Access to RNA Vaccines and Therapeutics with z- dbDNA

LISA CAPRONI, PH.D. As the global demand for RNA-based therapeutics and vaccines accelerates, traditional plasmid DNA (pDNA) production methods often ...
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery

Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery

Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery Published: 14 November 2024 Lisa Caproni, Ph.D. As gene therapy ...
Revolutionising the Genetic Medicine Landscape with Enzymatic DNA

Revolutionising the Genetic Medicine Landscape with Enzymatic DNA

Touchlight is pioneering the next generation of DNA manufacturing with our transformative dbDNA™ technology. The enzymatic DNA manufacturing platform sets ...
Transforming the Economics of AAV Production whilst Optimising Quality Using dbDNA™

Transforming the Economics of AAV Production whilst Optimising Quality Using dbDNA™

TOM MERRITT, PH.D. Traditional methods for the production of adeno-associated viral (AAV) vectors — crucial components in gene therapies — ...
MaxCyte-ondemand-webinar

Non-viral Cell Engineering with Stanford University, Touchlight, and MaxCyte: Advantages and Applications

Elena Stoyanova, Hyatt Balke-Want, Marianaa Romito, Debra Barberini In this virtual seminar, cell engineering scientists from Stanford University, Touchlight Genetics, ...
Touchlight-templates-WEBINAR

Optimizing Personalized Cancer Immunotherapy Manufacturing Using Enzymatic DNA

DR LISA CAPRONI & DR PIERRE MARSCHALL On-demand webinar (Recorded December 5, 2023)Nucleic acid vaccination is emerging as a potentially ...
Nature-publication

Nature Gene Therapy – Enzymatically amplified linear dbDNA as a rapid and scalable solution to lentiviral vector manufacturing

SARAH MOORE & MARIA BARREIRA With contribution by Helen Horton and Claire KerridgeTraditional bacterial fermentation techniques used to manufacture plasmid ...